Product Overview

Human Chorionic Gonadotropin 5000iu (HCG) is a recombinant glycoprotein hormone supplied as a sterile lyophilized powder in a single‑use glass vial. The product, branded by German Remedies Private Ltd, is indicated for the treatment of female infertility associated with ovulatory dysfunction. Each package contains one vial delivering 5000 international units (IU) of HCG, sealed in a tamper‑evident box. The formulation complies with WHO Good Manufacturing Practices (GMP) and is registered with the relevant national drug authorities. Storage requires a temperature of 2‑8°C until reconstitution, after which the solution remains stable for up to 24 hours at room temperature.

What is Human Chorionic Gonadotropin 5000iu?

Human Chorionic Gonadotropin is a hormone produced by the syncytiotrophoblast cells of the placenta after implantation. Structurally, HCG is a heterodimer composed of an α‑subunit shared with luteinizing hormone (LH), follicle‑stimulating hormone (FSH), and thyroid‑stimulating hormone (TSH), and a β‑subunit that confers biological specificity. In reproductive medicine, recombinant HCG mimics the endogenous LH surge that triggers the final maturation of ovarian follicles and ovulation. The 5000IU dose represents the standard therapeutic strength used in controlled ovarian stimulation protocols for assisted reproductive technologies (ART). Clinical pharmacology data indexed in PubMed demonstrate that recombinant HCG exhibits identical receptor binding affinity to native urinary HCG, with a reduced incidence of immunogenic reactions.

Uses and Benefits

The primary clinical use of HCG 5000IU is as a trigger agent in ovulation induction regimens for women undergoing in‑vitro fertilization (IVF) or intrauterine insemination (IUI). When administered at the appropriate follicular size (typically 18‑20 mm) and serum estradiol levels, HCG prompts the LH receptors on granulosa cells to initiate the cascade of events leading to oocyte maturation and release. Benefits documented in peer‑reviewed studies include higher ovulation rates, improved oocyte quality, and increased clinical pregnancy outcomes when combined with optimal stimulation protocols. Moreover, recombinant HCG reduces the risk of hypersensitivity compared with traditional urinary extracts, offering a safer option for patients with a history of allergic responses.

Beyond ovulation induction, HCG is occasionally employed in luteal phase support, where exogenous supplementation helps maintain progesterone production during the early weeks after embryo transfer. This adjunctive use can improve implantation rates, especially in patients with luteal phase deficiency.

How It Works

Pharmacodynamically, HCG binds to the LH/CG receptor (LHCGR) located on ovarian theca and granulosa cells. This interaction activates intracellular adenylate cyclase, leading to an increase in cyclic adenosine monophosphate (cAMP). The rise in cAMP stimulates the production of androgens in theca cells, which are subsequently aromatized to estrogen in granulosa cells, supporting follicular growth. The LH‑like activity of HCG ultimately triggers the rupture of the mature follicle, releasing the oocyte into the peritoneal cavity for subsequent fertilization. The hormone also supports the corpus luteum for approximately 10‑14 days, ensuring adequate progesterone levels until placental hormone production takes over.

Recombinant HCG exhibits a half‑life of approximately 30 hours after administration, which allows for a single‑dose trigger rather than multiple injections. Pharmacokinetic studies show that peak plasma concentrations are reached within 6‑12 hours, and elimination occurs primarily via renal clearance.

Dosage Guidelines

Dosage must be individualized by a qualified reproductive endocrinologist based on patient‑specific factors such as age, ovarian reserve, stimulation protocol, and response to prior cycles. The standard regimen for ovulation triggering involves a single intramuscular or subcutaneous injection of 5000IU once the leading follicle reaches a mean diameter of 18‑20 mm on transvaginal ultrasound and serum estradiol exceeds 200 pg/mL. In some protocols, a higher dose of 10,000IU may be utilized, but the 5000IU formulation remains the most widely adopted due to its proven efficacy and safety profile.

For luteal phase support, some clinicians administer a single dose of 5000IU on the day of embryo transfer, followed by daily supplementation of progesterone. Adjustments may be required in patients with polycystic ovary syndrome (PCOS) or those at risk of ovarian hyperstimulation syndrome (OHSS). Continuous monitoring via ultrasound and hormone assays is essential to mitigate complications.

Side Effects

Most adverse reactions to HCG 5000IU are mild and self‑limiting. Common side effects include headache, nausea, vomiting, and localized skin irritation at the injection site. Occasionally, patients may experience pelvic discomfort, breast tenderness, or transient bloating. Rare but serious complications can involve ovarian hyperstimulation syndrome, characterized by ascites, ovarian enlargement, and electrolyte imbalance, as well as thromboembolic events and allergic reactions. Patients should be instructed to report any severe abdominal pain, shortness of breath, or sudden weight gain immediately to their healthcare provider.

Post‑marketing surveillance data from the FDA’s Adverse Event Reporting System (FAERS) indicate a low incidence of serious adverse events when the drug is used according to labeling. Nevertheless, vigilant monitoring is recommended, especially in high‑risk populations.

Warnings and Precautions

HCG 5000IU is contraindicated in individuals with known hypersensitivity to the product or any of its excipients, as well as in patients who are pregnant or have hormone‑sensitive malignancies. Caution is advised for patients with a history of thromboembolic disease, ovarian cysts, or severe pelvic pathology. Concomitant use of other gonadotropins or ovulation‑inducing agents requires careful dose titration to avoid excessive ovarian stimulation. Prior to initiation, a baseline assessment of ovarian morphology and serum hormone levels should be performed, and ongoing surveillance with ultrasound is recommended throughout the stimulation cycle.

Healthcare professionals should also be aware of the potential for false‑positive pregnancy tests due to the exogenous hormone, which may persist in serum for up to 10 days after administration.

Frequently Asked Questions

1. What is the recommended storage condition for HCG 5000iu? The lyophilized powder should be stored refrigerated at 2‑8°C. After reconstitution with the supplied diluent, the solution can be kept at room temperature for a maximum of 24 hours; prolonged storage is not advised.

2. How is the medication administered? The powder is reconstituted using the accompanying sterile diluent and injected either intramuscularly into the gluteal muscle or subcutaneously into the abdominal wall. The injection should be performed with a sterile needle, and the site should be rotated to minimize tissue irritation.

3. Can HCG be used for male infertility? While HCG has off‑label applications in male infertility to stimulate testosterone production, this specific product is indicated for female infertility. Use in men should only occur under the supervision of a qualified physician and according to an individualized treatment plan.

4. Are there any drug interactions with HCG 5000iu? HCG does not possess significant cytochrome‑P450 activity, but concurrent use of other fertility medications such as gonadotropin‑releasing hormone (GnRH) agonists, clomiphene citrate, or letrozole may require dose adjustments. Always follow the prescribing clinician’s protocol to prevent overstimulation.

5. Where can I find authoritative scientific information? Detailed pharmacology, clinical trial results, and safety data are available from the U.S. National Library of Medicine’s PubMed database (https://pubmed.ncbi.nlm.nih.gov/) and the FDA’s drug label repository (https://www.fda.gov/drugs). Additional consumer‑focused information can be obtained from MedlinePlus (https://medlineplus.gov/druginfo/meds/a682025.html).

Related Products

• Azelastine Nasal Spray (Generic)
• Arzep Nasal Spray (Azelastine)
• Vigora 100 mg (Sildenafil Citrate)
• Vigora Tablet (Sildenafil Citrate)
• Vigora Lido Spray (Lidocaine)
• Vigore Gold 100 mg (Sildenafil Citrate)
• Vigore Force 80 mg (Sildenafil/Dapoxetine)
• Tadora 20 mg (Tadalafil)
• Vigora 50 mg (Sildenafil Citrate)
• Tadora Force 80 mg(Tadalafil/Dapoxetine)
• ZyhCG 10000 (HCG 10000iu)
• ZyhCG 5000 (HCG 5000iu)